Form 4: Ionis CEO Brett Monia Executes Stock Option Plan

Ionis Pharmaceuticals CEO Brett P. Monia exercised stock options and sold shares under a pre-established Rule 10b5-1 trading plan.

Summary

• CEO Brett P. Monia exercised options for 4,536 shares of common stock at an exercise price of $32.60.
• The shares were acquired on May 13 and May 14, 2026, and subsequently sold on the same dates.
• The sales were executed at weighted average prices of $78.013 and $78.6793 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine executive financial management.

Positives

• Transactions were executed under a pre-planned Rule 10b5-1 program, indicating systematic rather than discretionary selling.
• The CEO maintains a significant remaining beneficial ownership of 242,662 shares.

Negatives

• The filing reflects a reduction in the CEO's direct equity stake through the sale of 4,536 shares.

Risks

• Future share price volatility could impact the value of remaining unexercised options.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this disclosure.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice for executives in the biotechnology sector to manage personal liquidity and diversify holdings without signaling a lack of confidence in company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice for C-suite executives at large-cap biotech firms like Ionis to avoid potential insider trading allegations.
• The volume of shares sold represents a small fraction of the CEO's total holdings, which is consistent with typical executive compensation and retention strategies.

Stakeholder Impact

• Minimal impact on shareholders as the sales were pre-scheduled and represent a small portion of the CEO's total equity.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Brett Monia, Stock Options, Biotech